Mint reports, #Cipla #Chairman calls reports w.r.t promoter stake sale, #speculative
All reports of stake sales by the promoters are speculative, the clarifications w.r.t promoter stake sale reports, are made to exchanges, From Mint: Cipla Chairman at AGM
Alert: Cipla held its… https://t.co/WJKocb7TI4 https://t.co/VL3OyfbSAl
All reports of stake sales by the promoters are speculative, the clarifications w.r.t promoter stake sale reports, are made to exchanges, From Mint: Cipla Chairman at AGM
Alert: Cipla held its… https://t.co/WJKocb7TI4 https://t.co/VL3OyfbSAl
#Cipla | Food & Drugs Administration (#FDA), Konkan Division, suspend FDA licence of company’s Patalganga manufacturing unit for 10 days in December 2023 for non-conformance of good #manufacturing practices https://t.co/yqVUWAqxGV
Torrent Pharma seen in race to buy promoter stake in #Cipla, may need investor support for stake buy. PEs like Blackstone, baring PE asia-EQT also likely in the fray: Sources to @ekta_batra
Alert: CNBC-TV18 reported Cipla promoters likely to sell stake to PEs
Here's more… https://t.co/Im8qpMeKz2 https://t.co/CFqcrLpCmG
Alert: CNBC-TV18 reported Cipla promoters likely to sell stake to PEs
Here's more… https://t.co/Im8qpMeKz2 https://t.co/CFqcrLpCmG
GST Council Likely To Give Relief On A Slew Of Cancer Drugs: Sources to TimsyJaipuria
📌Tax on Trastuzumab Deruxtecan, Osimertinib & Durvalumab can be cut to 5% from 12%
📌Fitment panel’s recommendations based on proposal shared by Health Ministry
📌Alert: Manufacturers of these #CancerDrugs are #Abbott, #ZydusLife, #Alkem, #RelianceLife, #Cipla, #Mylan & #Biocon
📌Alert: 54th #GSTCouncil to meet on September 9 in Delhi
📌Tax on Trastuzumab Deruxtecan, Osimertinib & Durvalumab can be cut to 5% from 12%
📌Fitment panel’s recommendations based on proposal shared by Health Ministry
📌Alert: Manufacturers of these #CancerDrugs are #Abbott, #ZydusLife, #Alkem, #RelianceLife, #Cipla, #Mylan & #Biocon
📌Alert: 54th #GSTCouncil to meet on September 9 in Delhi